RxDoctor Payments Data

David Millili, DPM

Foot Surgery · Camden, NJNPI 1053495408

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Organogenesis Inc. at 36.6% of the total. Reporting peaked in 2023 at $230 and has fallen 80.7% since, to $44 in 2025. That places this record below the midpoint for foot surgery clinicians in NJ, where the typical reported total is $943.

$1,007in general payments, 2019–2025

Across 31 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$369
  • Stryker$298
  • Kerecis Limited$139
  • Smith+Nephew$104
  • Bard Peripheral Vascular, Inc.$26
  • Orthofix Medical, Inc.$22
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 50th percentile of 59 foot surgery providers in New Jersey.

See all foot surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$71,747
Medicare patients
286
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.40$17,634
Ammonium Lactate110$2,347
Ciclopirox43$1,377
Halobetasol Propionate18$837
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip40$652
Gabapentin30$259
Doxycycline Monohydrate24$229
Meloxicam54$150
Cephalexin23$92
Terbinafine Hcl11$92
SsdSilver Sulfadiazine11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$104$17,63440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 59 foot surgery providers in New Jersey.

Other foot surgery in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →